Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07388511 · ClinicalTrials.gov registry record · Phase 1

A Study of Elenestinib in Healthy Adult Female Participants

A Phase 1 study of Healthy Participants, sponsored by Blueprint Medicines Corporation.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT07388511: Recruiting Phase 1 study of Healthy Participants, sponsored by Blueprint Medicines Corporation.

NCT07388511 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Blueprint Medicines Corporation. The registered enrollment target is 20 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07388511, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Blueprint Medicines Corporation.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.

Conditions Studied

Interventions

  • DRUG Midazolam
  • DRUG Levonorgestrel/Ethinyl Estradiol
  • DRUG Elenestinib

Study Locations (1)

Arizona

  • Celerion, Inc - Tempe

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-02-03
Est. Completion 2026-04-01
Phase Phase 1
Blueprint Medicines Corporation

24 total trials

What NCT07388511 shows while recruiting

NCT07388511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (69% lower).

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Midazolam is the first listed.

NCT07388511 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT07388511 about?

NCT07388511 is a clinical study titled "A Study of Elenestinib in Healthy Adult Female Participants". The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estra...

What is the current status of trial NCT07388511?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-02-03. Estimated completion is 2026-04-01.

What conditions does trial NCT07388511 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT07388511?

The interventions under investigation include: Midazolam (DRUG), Levonorgestrel/Ethinyl Estradiol (DRUG), Elenestinib (DRUG).

Who is sponsoring clinical trial NCT07388511?

This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07388511 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07388511's enrollment target sits among peer trials

20 91st of 119 higher than 26 of 119 other Healthy Participants trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07388511, the US trial registry maintained by the National Library of Medicine. NCT07388511 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.